Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Biomaterials ; 33(5): 1563-72, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22098778

ABSTRACT

Rheumatoid arthritis (RA) is a systemic autoimmune disease that is initiated and maintained by various inflammatory/immune cells and their cytokines, leading to cartilage degradation and bone erosion. Despite its potent therapeutic efficacy on RA, the oral administration of methotrexate (MTX) provokes serious adverse systemic complications, thus necessitating the local application of MTX. Here, we show that transcutaneous MTX (TC-MTX) can efficiently penetrate joint skin ex vivo and in vivo, and that TC-MTX can significantly improve the various inflammatory symptoms associated with RA. Further, TC-MTX preserved the joint-structures in mice with collagen-induced arthritis (CIA), which was also confirmed by three-dimensional micro-computed tomography scan. TC-MTX markedly decreased the secretion of inflammatory cytokines both in the serum and in inflamed joints of CIA mice. Further, its therapeutic potential is comparable to that of etanercept, a biological agent that block tumor necrosis factor (TNF)-α. Importantly, the systemic cytotoxicity of TC-MTX was not detected. Thus, TC-MTX can be a new therapeutic modality for RA patients without systemic complications.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Cell Membrane Permeability/drug effects , Drug Delivery Systems/methods , Methotrexate/pharmacology , Methotrexate/therapeutic use , Administration, Cutaneous , Animals , Arthritis, Experimental/drug therapy , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/diagnostic imaging , Arthritis, Rheumatoid/pathology , Cell Death/drug effects , Cytokines/metabolism , Dose-Response Relationship, Drug , Etanercept , Immunoglobulin G/pharmacology , Immunoglobulin G/therapeutic use , Inflammation Mediators/metabolism , Kinetics , Male , Methotrexate/administration & dosage , Methotrexate/chemistry , Mice , Receptors, Tumor Necrosis Factor/therapeutic use , Tetrahydrofolate Dehydrogenase/metabolism , Tissue Distribution/drug effects , Treatment Outcome , X-Ray Microtomography
2.
Stem Cells ; 27(9): 2283-92, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19544472

ABSTRACT

Mesenchymal stem cell (MSC) therapy for myocardial injury has inherent limitations due to the poor viability of MSCs after cell transplantation. In this study, we directly delivered Hsp70, a protein with protective functions against stress, into MSCs, using the Hph-1 protein transduction domain ex vivo for high transfection efficiency and low cytotoxicity. Compared to control MSCs in in vitro hypoxic conditions, MSCs delivered with Hph-1-Hsp70 (Hph-1-Hsp70-MSCs) displayed higher viability and anti-apoptotic properties, including Bcl2 increase, reduction of Bax, JNK phosphorylation and caspase-3 activity. Hsp70 delivery also attenuated cellular ATP-depleting stress. Eight animals per group were used for in vivo experiments after occlusion of the left coronary artery. Transplantation of Hph-1-Hsp70-MSCs led to a decrease in the fibrotic heart area, and significantly reduced the apoptotic positive index by 19.5 +/- 2%, compared to no-treatment controls. Hph-1-Hsp70-MSCs were well-integrated into the infarcted host myocardium. The mean microvessel count per field in the infarcted myocardium of the Hph-1-Hsp70-MSC-treated group (122.1 +/- 13.5) increased relative to the MSC-treated group (75.9 +/- 10.4). By echocardiography, transplantation of Hph-1-Hsp70-MSCs resulted in additional increases in heart function, compared to the MSCs-transplanted group. Our results may help formulate better clinical strategies for in vivo MSC cell therapy for myocardial damage.


Subject(s)
Carrier Proteins/genetics , Cell Death/physiology , Cell Hypoxia/physiology , HSP70 Heat-Shock Proteins/physiology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Myocardial Infarction/therapy , Adenosine Triphosphate/metabolism , Animals , Caspase 3/metabolism , Cell Death/genetics , Cell Hypoxia/genetics , Cell Survival/genetics , Cell Survival/physiology , Cells, Cultured , HSP70 Heat-Shock Proteins/genetics , Immunohistochemistry , In Situ Nick-End Labeling , Male , Mesenchymal Stem Cell Transplantation/methods , Polycomb Repressive Complex 1 , Rats , Rats, Sprague-Dawley
3.
Proc Natl Acad Sci U S A ; 105(50): 19875-80, 2008 Dec 16.
Article in English | MEDLINE | ID: mdl-19066215

ABSTRACT

CTLA-4 (CD152) negatively regulates T cell activation signaling, and the cytoplasmic domain of CTLA-4 (ctCTLA-4) itself has the capacity to inhibit T cell activation in vitro and in vivo. In this study, the inhibitory mechanisms of the cell-permeable recombinant protein Hph-1-ctCTLA-4 on T cell activation and its ability to prevent collagen-induced arthritis were analyzed. Hph-1-ctCTLA-4 prevented human and mouse T cell activation and proliferation by inhibition of T cell receptor-proximal signaling and the arrest of the cell cycle. Furthermore, Hph-1-ctCTLA-4 protected human umbilical vein endothelial cells (HUVEC) from the human CTL allo-response. The incidence and severity of collagen-induced arthritis were significantly reduced and the erosion of cartilage and bone was effectively prevented by i.v. injection and transdermal administration of Hph-1-ctCTLA-4. Inflammatory cytokine production (IL-1beta, IL-6, TNF-alpha, IL-17A) and collagen-specific antibody levels were significantly reduced, and the numbers of activated T cells and infiltrating granulocytes were substantially decreased. These results demonstrate that systemic or transdermal application of a cell-permeable form of the cytoplasmic domain of CTLA-4 offers an effective therapeutic approach for autoimmune diseases such as rheumatoid arthritis.


Subject(s)
Antigens, CD/genetics , Arthritis, Experimental/prevention & control , Carrier Proteins/genetics , Recombinant Proteins/genetics , Animals , Arthritis, Experimental/pathology , CTLA-4 Antigen , Cartilage, Articular/immunology , Cartilage, Articular/pathology , Cytoplasm/immunology , Disease Models, Animal , Humans , Joints/immunology , Joints/pathology , Lymphocyte Activation , Mice , Polycomb Repressive Complex 1 , Receptors, Antigen, T-Cell/antagonists & inhibitors , T-Lymphocytes/immunology , Transduction, Genetic
4.
Mol Cancer Ther ; 5(12): 3222-31, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17172426

ABSTRACT

Tautomycetin is an antifungal antibiotic retaining potent immunosuppressive function. We have identified the roles of tautomycetin on cellular proliferation and transformation of colorectal cancer cells. The proliferation and anchorage-independent growth of HCT-15, HT-29, and DLD-1 colorectal cancer cells were efficiently inhibited without induction of apoptosis by 150 nmol tautomycetin. These growth inhibitory effects were dependent on p21Cip/WAF induction via the extracellular signal-regulated kinase pathway, and the tautomycetin effects were abolished in HCT-116 colon cells and eight other types of cells that did not induce p21Cip/WAF by 150 nmol tautomycetin. The crucial role of p21Cip/WAF1 in the extracellular signal-regulated kinase pathway-dependent antiproliferative responses by tautomycetin was confirmed by using p21Cip/WAF1 gene-deleted HCT-116 cells. The growth inhibitory effect of tautomycetin was acquired by regulation of Raf-1 activity through inhibition of protein phosphatase type 1 and protein phosphatase type 2A with high preference toward protein phosphatase type 1. Tautomycetin could be a potential drug for colorectal cancer.


Subject(s)
Colorectal Neoplasms/drug therapy , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Extracellular Signal-Regulated MAP Kinases/metabolism , Furans/pharmacology , Lipids/pharmacology , Animals , COS Cells , Cell Nucleus/metabolism , Chlorocebus aethiops , Colorectal Neoplasms/genetics , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Enzyme Activation/drug effects , G1 Phase/drug effects , HCT116 Cells , HT29 Cells , HeLa Cells , Humans , MAP Kinase Kinase Kinases/metabolism , MAP Kinase Signaling System/drug effects , Mice , NIH 3T3 Cells , Phosphoprotein Phosphatases/metabolism , Proto-Oncogene Proteins c-raf/metabolism , S Phase/drug effects
5.
Nat Med ; 12(5): 574-9, 2006 May.
Article in English | MEDLINE | ID: mdl-16604087

ABSTRACT

CTLA-4 is a negative regulator of T-cell activation, and its inhibitory effects can be accomplished either by competition with CD28 or by transmitting negative signals through its intracellular domain. To utilize the cytoplasmic domain of CTLA-4 to suppress allergic inflammation, we fused it to a novel protein-transduction domain in the human transcriptional factor Hph-1. Transduction efficiency was verified in vitro and in vivo after ocular, intranasal and intradermal administration. After transduction into T cells, the Hph-1-ctCTLA-4 fusion protein inhibited the production of interleukin (IL)-2, and downregulated CD69 and CD25. Intranasal administration of Hph-1-ctCTLA-4 resulted in markedly reduced infiltration of inflammatory cells, secretion of T helper type 2 (T(H)2) cytokines, serum IgE levels and airway hyper-responsiveness in a mouse model of allergic airway inflammation. These results indicated that Hph-1-ctCTLA-4 constitutes an effective immunosuppressive protein drug for potential use in the treatment of allergic asthma, via nasal administration.


Subject(s)
Administration, Intranasal , Antigens, Differentiation/administration & dosage , Antigens, Differentiation/immunology , Asthma , Carrier Proteins/metabolism , Immunosuppressive Agents , Inflammation , Animals , Antigens, CD , Antigens, Differentiation/genetics , Asthma/immunology , Asthma/prevention & control , Bronchial Hyperreactivity , CTLA-4 Antigen , Carrier Proteins/genetics , Female , Humans , Immunoconjugates/administration & dosage , Immunoconjugates/genetics , Immunoconjugates/immunology , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/immunology , Inflammation/immunology , Inflammation/prevention & control , Male , Mice , Mice, Inbred BALB C , Ovalbumin/immunology , Polycomb Repressive Complex 1 , Protein Structure, Tertiary , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Transduction, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...